Selected Scientific Presentations

Since 2015

2018

European Health Economics Association (EuHEA) Conference 2018
Maastricht / The Netherlands, July 11-14, 2018:

Michael Schlander, Oliver Schwarz, Diego Hernández, Ramon Schaefer:

The Value of a Statistical Life Year (VSLY) – An Analysis of Empirical Economic Studies from 1995 to 2015.

Michael Schlander, Harry Telser, Barbara Fischer, Tobias von Rechenberg, Ramon Schaefer – on behalf of the ESPM Project Group:

Attributes of Health Care Interventions that drive Social Willingness-To-Pay: Focus on Rarity (Insights from a Discrete Choice Experiment in Switzerland).

Barbara Fischer, Harry Telser, Tobias von Rechenberg, Ramon Schaefer, Michael Schlander – on behalf of the ESPM Project Group:

Hypothetical bias and the role of information in discrete choice experiments.

Recent Scientific Presentation at the Institute for Quality and Efficiency in Health Care (IQWiG)
Cologne / Germany, July 09, 2018:

Michael Schlander:

Measuring Health-Related Quality of Life: German Patient Preferences for Generic Health States – Research based on the Multi-Instrument Comparison (MIC) Study.

International Workshop on “Health Systems Resilience for Rare Diseases”
Paris / France, June 27, 2018:

Michael Schlander:

Sustainability: Budgetary Impact and Cost Drivers for Rare and Ultra-Rare Diseases.

HTAi 2018 Annual Meeting
Vancouver / Canada, June 01-05, 2018:

Michael Schlander, Oliver Schwarz, Diego Hernández, Ramon Schaefer:

The Search for a Cost Effectiveness Standard: 1-3 Times GDP/Capita?

Michael Schlander, Harry Telser, Barbara Fischer, Tobias von Rechenberg, Ramon Schaefer – on behalf of the ESPM Project Group:

Social Preferences for Health Care Interventions: The SoPHI Study.

ISPOR 2018 International Conference
Baltimore, MD / United States, May 19–23, 2018:

Michael Schlander, Oliver Schwarz, Diego Hernández, Ramon Schaefer:

New Estimates of the Willingness-To-Pay for a Statistical Life Year: A Systematic Review of the Empirical Economic Literature.

Michael Schlander, Harry Telser, Barbara Fischer, Tobias von Rechenberg, Ramon Schaefer – on behalf of the ESPM Project Group:

Should Rarity Matter? Results of a Social Willingness-To-Pay Study using the Discrete Choice Experiment (DCE) Method in Switzerland.

International Symposium on "Economical Perspectives in Rare Diseases (Theme 5)":
"A Paradigm Shift in Value Frameworks For Access" (Session 0503)
(Theme Leader & Session Chair: Prof Michael Schlander)

9th European Conference on Rare Diseases & Orphan Products (ECRD)
Vienna / Austria, May 10-12, 2018:

Prof Michael Schlander (DKFZ & University of Heidelberg, Germany):

Introduction:
"Economical Perspectives in Rarae Diseases: A Paradigm Shift in Value Frameworks for Access".

Prof Michael Schlander (DKFZ & University of Heidelberg, Germany):

Economical Perspectives in Rare Diseases - A Paradigm Shift in Value Frameworks for Access.

Prof Jeff Richardson (Monash University, Melbourne, Australia):

How should we allocate the budget: Efficiency of fairness first.

Sheela Upadhyaya (NICE HST Programme, United Kingdom):

Highly Specialised Technologies Programme at NICE.

2017

International Symposium on "Accessibility to High-Value Medicines"
London School of Hygiene & Tropical Medicine, England, December 6, 2017:

Michael Schlander:

"Social Willingness to Pay" and the Case for "Social Cost Value Analysis"

ISPOR 20th Annual European Congress
Glasgow / Scotland, November 04-08, 2017:

In addition to five scientific contributions on the current practice and the future of Health Technology Assessments (HTAs), alternatives to the logic of cost effectiveness, new European evidence on the economic value of a statistical life year, and the practice of pharmaceutical expenditure projections, Michael Schlander was interviewed by Cathy Jordan of GalbraithWight. Here are his answers to four questions she asked, i.e.,

1. on his vision for the new Division of Health Economics at the German Cancer Research Center (DKFZ) in Heidelberg, Germany

2. on the need for an improved (or even alternative) health economic evaluation model that better captures social value, and the promise and implications of "social cost value analysis" in the context of Health Technology Assessments (HTAs)

3. on some of the challenges surrounding defensible pharmaceutical pricing and reimbursement policies, considering the cost structure of the research-based biopharmaceutical industry

4. on the analytical gap between concerns about affordability and budget impact analyses on the one hand, and conventional health economic evaluations on the other hand

HTAi 2017 Annual Meeting
Rome / Italy, June 17-21, 2017:

Michael Schlander, Ramon Schaefer, Oliver Schwarz:

An Update on the Economic Value of a Statistical Life Year in Europe.

Ramon Schaefer, Michael Schlander:

Is NICE in the UK more Innovation-Friendly than IQWiG/GBA in Germany?

MedTech Dialogue Meeting
Mannheim / Germany, March 23, 2017:

Health Technology Assessment (HTA) for Medical Products – How to Cope with the Increasing Regulatory Burden?

In Germany, market access for medical devices and procedures is regulated by complex processes. Recent changes have raised the bar as to the expected level of evidence regarding clinical effectiveness. At the same time, coverage with evidence regimens (according to SGB V §§137e and 137h) have been introduced as a new pathway to reimbursement, creating opportunities for manufacturers and hospitals.

Second EURORDIS Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies
Brussels / Belgium, February 23, 2017:

Michael Schlander:

Common Principles for Value Determination and Assessment.

Orphan drug regulation has been a great success in terms of stimulating research and development (R&D). With this success, pricing strategies of manufacturers of orphan medicinal products (OMPs) have become a reason of growing concern for policy makers and health care budget holders. High prices have traditionally been justified by the fixed cost caused by high out-of-pocket expenses, development times, and risk of failure associated with R&D into innovative medical technologies. In this environment, it is creating inconsistencies if and when manufacturers push for adaptive licensing and rapid market access – as this would necessarily imply not only undermining rigorous Health Technology Assessments, but simultaneously shifting risks and costs to other stakeholders, including patients.

2016

„5 Jahre Cluster Medizintechnologie – 5 Jahre Fraunhofer-Projektgruppe PAMB in Mannheim“
Official Celebration,  Mannheim / Germany, December 08, 2016:

Michael Schlander:

Neue Innovationsmodelle für die Gesundheitsversorgung der Zukunft.

(Invited keynote address)

Annual Meeting 2016 of the German Professional Association of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy
(Jahrestagung des Berufsverbands für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie in Deutschland, BKJPP, mit dem Leitthema „Sprache[n] in der Kinder- und Jugendpsychiatrie“)
Regensburg / Germany, November 03, 2016:

Michael Schlander:

Sprache(n) der Gesundheitsökonomie.

(Invited plenary lecture)

International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
19th Annual European Congress, Vienna / Austria, October 29 – November 02, 2016:

Michael Schlander, Kathrin Stenner, Afschin Gandjour:

Drugs for Rare and Ultra-Rare Diseases in Europe: Analysis of Budget Impact and Cost Drivers.

(Research Poster Presentation, November 01, 2016)
Value in Health 19 (7), 2016: A598.

Michael Schlander, Harry Telser, Søren Holm, Deborah Marshall, Erik Nord, Jeff Richardson, Silvio Garattini, Peter Kolominsky-Rabas, Ulf Persson, Maarten Postma, Steven Simoens, Oriol de Solà-Morales, Keith Tolley, Mondher Toumi:

The European Social Preference Measurement (ESPM) Study: Conceptual Considerations and Implementation.

(Research Poster Presentation, October 31, 2016)
Value in Health 19 (7), 2016: A508.

The preliminary study design discussed at ISPOR was based on a consensus achieved at a joint Scientific Steering Committee and International Advisory Board meeting in conjunction with the

Heidelberg Health Economics Summer School 2016,
Heidelberg / Germany: September 26-28, 2016:

Workshop “SoPHI: ‘Social Preferences for Health Care Interventions’”: Pre-Test Questionnaire Design for the European Social Preferences (ESPM) Study Project, Phase I (September 28, 2016)

11th European Conference on Health Economics (“Know the Ropes – Balancing Costs and Quality in Health Care”)
Hamburg / Germany, July 13-16, 2016:

Paul M. Mitchell, Hareth Al-Janabi, Michael Schlander, Jeff Richardson, Angelo Iezzi, Joanna Coast:

Verstehen Sie? Validating the German translation of the ICECAP-A capability wellbeing measure in seven disease groups and a healthy population sample.

(Oral Presentation, July 16, 2016) Conference Booklet, p. 66.

Michael Schlander, Munir A. Khan, Angelo Iezzi, Aimee Maxwell, Oliver Schwarz, Jeff Richardson:

Multi-Attribute Utility (MAU) Instruments as Tools to Value Health-Related Quality of Life:
German Findings from the MIC Study.

(Oral Presentation, July 16, 2016) Conference Booklet, p. 71.

8th European Conference on Rare Diseases & Orphan Products (ECRD 2016)
Symposium on “Game Changers in Research”, Edinburgh / Scotland, May 26-28, 2016:

Michael Schlander, Søren Holm, Erik Nord, Jeff Richardson, Silvio Garattini, Peter Kolominsky-Rabas, Deborah Marshall, Ulf Persson, Maarten Postma, Steven Simoens, Oriol de Solà Morales, Keith Tolley, Mondher Toumi, Harry Telser:

The European Social Preferences Measurement (ESPM) study project: social cost value analysis, budget impact, commercial life cycle revenue management, and the economics of biopharmaceutical Research & Development (R&D).

(Invited Presentation, May 28, 2016)
Abstract published in Orphanet Journal of Rare Diseases, 11, Suppl. 1 (2016): 143.

2015

Health Economics Global Congress 2015 Europe
London / England, December 06-07, 2015:

Michael Schlander:

“The Burning Platform”:  Credibility of Corporate Health Economics.

(Invited Presentation, December 07, 2015)

International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
18th Annual European Congress, Milan / Italy, November 07 – November 11, 2015:

Michael Schlander, Oliver Schwarz, Goetz-Erik Trott, Tobias Banaschewski:

Mental Health Disorder Prevalence Trends in Germany: A Longitudinal Study.

(Research Poster Presentation)
Value in Health 18 (7), 2015: A408.

2nd International Scientific and Practical Conference “Health Technology Assessment: Ways of Development in Russia”
Moscow / Russia, November 02, 2015:

Michael Schlander:

The Rationale for Multi-Criteria Decision Analysis (MCDA) as a Tool of HTA.

(Invited Presentation)

2015 HTAi International Conference
Oslo / Norway, June 14-17, 2015:

Mireille Goetghebeur, Bjorn Hofmann, Alaa Hamed, Michael Schlander, Carole Longson, Payam Abrishami, Francois Meyer:

Communicating values and ethics across the healthcare decision-making continuum: where are we and what holistic multicriteria brings?

(Poster Presentation)

Michael Schlander, Søren Holm, Erik Nord, Jeff Richardson:

Improving the Usefulness of Health Economic Evaluations for Decision Makers: Social Value and the Case of Interventions for Rare and Ultra-Rare Disorders (URDs).

Workshop (moderated by Deborah Marshall, Calgary) held at HTAi conference in Oslo / Norway, June 17, 2015

ISPOR 20th Annual International Meeting
Philadelphia, PA / USA, May 16-20, 2015:

Zeba M. Khan, Michael Schlander, Ron Akehurst, John Proach:

The Controversial Role of Cost-Effectiveness Analyses (CEA) and Incremental Cost-Effectiveness Ratio (ICER) Thresholds in Value-Based Assessments (VBA) of Health Technologies: What are the Future Challenges?

Invited Presentation to Issues Panel held at ISPOR International Meeting, Philadelphia, PA / USA, May 19, 2015.

Michael Schlander, Silvio Garattini, Søren Holm, Peter Kolominsky-Rabas, Erik Nord, Ulf Persson, Maarten Postma, Jeff Richardson, Steven Simoens, Oriol Sola Morales, Keith Tolley, Mondher Toumi:

Interventions for Ultra-Rare Disorders (URDs) and the Logic of Cost Effectiveness.

Invited Podium Presentation to ISPOR International Meeting, Philadelphia, PA / USA, May 18, 2015.
Value in Health 18 (3), May 2015: A6.